eFFECTOR Therapeutics, Inc.

The momentum for this stock is not very good. eFFECTOR Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in eFFECTOR Therapeutics, Inc..

News

Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%

Benzinga EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated its employees and will wind down its operations.\n more…

The end of eFFECTOR Therapeutics: Oncology biotech winds down after mid-stage fail

FierceBiotech.com - Biotech The end of eFFECTOR Therapeutics: Oncology biotech winds down after mid-stage fail\ngmasson\nMon, 06/24/2024 - 10:19...\n more…

eFFECTOR Therapeutics to wind down operations, expects to be delisted from Nasdaq

Seeking Alpha - Healthcare eFFECTOR Therapeutics to wind down operations, expects to be delisted from Nasdaq...\n more…

eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

Globe Newswire SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will...\n more…

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Sees Large Drop in Short Interest

Ticker Report eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR - Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 110,700 shares, a decrease...\n more…

eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…